The potential for improvement of outcomes by personalized insulin treatment of type 1 diabetes as assessed by analysis of single-patient data from a randomized controlled cross-over insulin trial

详细信息    查看全文

• 作者：Ulrik Pedersen-Bjergaard^a ; ⁱ ; ^{ulpebj@noh.regionh.dk} ; Peter L. Kristensen^a ; Henning Beck-Nielsen^c ; ^j ; Kirsten Nø ; rgaard^d ; Hans Perrild^e ; Jens S. Christiansen^f ; ^k ; ¹ ; Tonny Jensen^g ; Hans-Henrik Parving^g ; ^k ; Birger Thorsteinsson^a ; ⁱ ; Lise Tarnow^b ; ^h ; ^k
• 关键词：EMA ; European Medicines Agency ; FDA ; The Food and Drug Administration ; NPH ; neutral protamine hagedorn ; PROBE ; prospective ; randomised ; open ; blinded endpoint
• 刊名：Diabetes Research and Clinical Practice
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：123
• 期：Complete
• 页码：143-148
• 全文大小：486 K
• 卷排序：123

文摘

A cross-over trial comparing two insulin regimens was analyzed at patient level. Fourty-nine % had better outcome with insulin analogs and 25% with human insulin. Choosing the best individual treatment improved the overall outcome significantly. This supports the importance of personalized insulin treatment in type 1 diabetes.